Predictive and prognostic value of serum AFP level and its dynamic changes in advanced gastric cancer patients with elevated serum AFP

Table 1 Univariate prognostic analysis of clinicopathological features n (%)

Variable	AFPAGC(n = 105)	Median OS (mo)	P value
Sex
Male	82 (78.1)	15.0	0.144
Female	23 (21.9)	11.3
Age (yr)
≥ 60	49 (46.7)	15.0	0.189
< 60	56 (53.3)	12.0
Serum AFP level (ng/mL)
≥ 500	37 (35.2)	13.0	0.806
< 500	68 (64.5)	14.6
Primary lesion site
EGJ	41 (39.8)	15.0	0.245
Non-EGJ	62 (60.2)	12.0
Differentiation degree
Well	30 (29.4)	15.4	0.496
Poor	66 (64.7)	12.9
HAS	6 (5.9)	4.5
Lauren classification
Intestinal	45 (57.0)	15.4	0.352
Non-intestinal	34 (43.0)	14.6
HER2 status
Positive	20 (24.4)	17.5	0.583
Negative	62 (75.6)	14.6
LM
Present	63 (60.0)	12.0	0.048a
Absent	42 (40.0)	16.7
Peritoneal metastasis
Present	16 (15.4)	6.17	0.001a
Absent	88 (84.6)	15.2
Non-regional LNM
Present	56 (53.3)	11.0	0.042a
Absent	49 (46.7)	17.9
Other hematogenous metastasis
Present	27 (25.7)	10.5	0.004a
Absent	78 (74.3)	17.5
PVTT
Present	13 (12.4)	8.3	0.011a
Absent	92 (87.6)	15.0
First-line regimen
Doublet regimen	89 (88.1)	14.6	0.850
Triplet regimen	12 (11.9)	15.1
Evaluation
PR	42 (48.3)	17.6	0.007a
SD + PD	45 (51.7)	11.1
AFP decline degree
≥ 50%	49 (55.7)	17.5	0.003a
< 50%	39 (44.3)	10.0
Local treatment for LM
Yes	19 (18.1)	17.9	0.215
No	86 (81.9)	12.9

^aP < 0.05. GEJ: Gastroesophageal junction; HER2: Human epidermal growth factor receptor-2; AFP: α-fetoprotein; LM: Liver metastasis; LNM: Lymph node metastasis; PVTT: Portal vein tumor thrombus.